• Home
  • Latest
  • Fortune 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Right Arrow Button IconLeft Arrow Button IconHome
Right Arrow Button IconPfizer

Pfizer

Page 35 of 37
ECB President Mario Draghi Rates Conference
FinanceMarkets Fall On Draghi Misfire
By Alan MurrayDecember 4, 2015
Cindy Whitehead, chief executive officer of Sprout Pharmaceuticals Inc., speaks during a Bloomberg Television interview in New York, U.S., on Wednesday, Aug. 19, 2015. Whitehead discussed Addyi, the company's pill for low libido in women that won approval from the U.S. Food and Drug Administration yesterday. Photographer: Chris Goodney/Bloomberg *** Local Caption *** Cindy Whitehead
MPWSprout’s CEO On Why We Should Stop Calling Addyi ‘the Female Viagra’
By Kia KokalitchevaDecember 1, 2015
Pfizer CEO Ian Read
FinancePfizer Says No Merger Tax Help For Our Top Execs
By Dan PrimackNovember 25, 2015
Pfizer CEO Ian Read
LeadershipPfizer’s CEO Isn’t a Hero or a Villain
By Geoff ColvinNovember 25, 2015
LeadershipWhy Washington is Tackling the Tax Inversion Problem All Wrong
By Chris MatthewsNovember 25, 2015
Pfizer In Merger Talks With Allergan PLC
FinancePfizer’s Allergan Deal is an Even Bigger Tax Dodge Than It’s Claiming
By Stephen GandelNovember 24, 2015
Pfizer In Merger Talks With Allergan PLC
FinanceInvestors Aren’t Convinced the Pfizer-Allergan Deal is a Go
By Stephen GandelNovember 23, 2015
American Pharmaceutical Company Pfizer Propose To Takeover British AstraZeneca
FinanceWill the Pfizer Inversion Get It Booted From the Dow?
By Chris MatthewsNovember 23, 2015
Pfizer In Merger Talks With Allergan PLC
FinancePfizer/Allergan deal pushes 2015 into the record books
By Dan PrimackNovember 23, 2015
HealthPrediction: Healthcare’s M&A Flood Will Ebb in 2016
By Jen WiecznerNovember 23, 2015
Inside The Pfizer Inc. Kendall Square Research Facility Ahead Of Earnings Figures
FinanceWhy New Tax Inversion Rules Won’t Stop Pfizer-Allergan Deal
By Stephen GandelNovember 20, 2015
Pfizer In Merger Talks With Allergan PLC
LeadershipWill Lobbying Dollars Put Pfizer and Allergan On The Fast Track?
By Paul HodgsonNovember 20, 2015
Pfizer employees inside of a laboratory at Pfizer's research and development facility in Cambridge, Massachusetts, U.S., on Monday, Oct. 26, 2015. Photographer: Scott Eisen/Bloomberg *** Local Caption ***
FinanceWhy Pfizer Is Headed for Splitsville After Allergan Merger
By Jen WiecznerNovember 19, 2015
Pfizer And AstraZeneca's Billion Dollar Battle
LeadershipA Pfizer Deal With Allergan Would Add Fuel to the Fight Over Taxes
By Alan MurrayNovember 19, 2015
Views of The Facebook Inc. Logo Ahead of Earnings
TechVW’s New Horror And Facebook 3Q–5 Things To Know Today
By Laura Lorenzetti and Geoffrey SmithNovember 4, 2015
1...
  • 33
  • 34
  • 35
  • 36
  • 37
37
Most Popular
Law
DOGE cancelled a $349,000 grant to replace a museum’s HVAC after ChatGPT flagged it as DEI, court documents showAn image of a popular article
By Fortune EditorsMarch 19, 2026
Economy
Social Security has 6 years left. The fix that sounds cruelest may be the smartestAn image of a popular article
By Fortune EditorsMarch 19, 2026
Success
Less than 10 out of 250 billionaires have kept their promise to give away their fortune—and a philanthropy CEO says Elon Musk is right about why: 'It's hard'An image of a popular article
By Fortune EditorsMarch 18, 2026
Fortune Secondary Logo
Rankings
  • 100 Best Companies
  • Fortune 500
  • Global 500
  • Fortune 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Fortune Crypto
  • Features
  • Leadership
  • Health
  • Commentary
  • Success
  • Retail
  • Mpw
  • Tech
  • Lifestyle
  • CEO Initiative
  • Asia
  • Politics
  • Conferences
  • Europe
  • Newsletters
  • Personal Finance
  • Environment
  • Magazine
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Fortune Brand Studio
  • Fortune Analytics
  • Fortune Conferences
  • Business Development
  • Group Subscriptions
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Fortune
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

© 2026 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Fortune Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.